+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the drug CMG190303 for treating adults with Type 2 Diabetes and Dyslipidemia. This phase III trial aims to compare how CMG190303 affects blood sugar control measured by HbA1c and cholesterol levels measured by LDL-C over 24 weeks, compared to two other treatments Rosuvastatin and Dapagliflozin. The study also monitors the safety of CMG190303 throughout the treatment period. Participants are randomly assigned to one of three groups those receiving CMG190303 a combination of Dapagliflozin and Rosuvastatin with doses increasing over 24 weeks, a group receiving Dapagliflozin with a Rosuvastatin placebo, or a group receiving Rosuvastatin with a Dapagliflozin placebo. The dosing schedule adjusts every 8 weeks with increasing amounts for both drugs in the CMG190303 group, while the placebo groups maintain consistent dosing. The trial is double-blinded, meaning neither participants nor researchers know which treatment is given. During the study, participants will have regular assessments to measure their HbA1c and LDL-C levels at various points up to 24 weeks. Additional blood tests will monitor fasting plasma glucose and other lipid parameters at 8, 16, and 24 weeks. Medication adherence is tracked, and safety monitoring is ongoing. The total participation duration is 24 weeks of treatment, during which researchers collect data to understand the drugs effects and safety in adults with these conditions.

Age: 19Years - 80YearsAll GendersPhase 3
24 locations
G

Actively Recruiting

Researchers are observing the long-term clinical outcomes for patients with unprotected left main coronary artery LMCA disease. The study aims to compare results of different treatments including medical therapy, coronary stenting with drug-eluting stents, and coronary artery bypass grafting CABG in routine clinical practice. This large, multicenter registry collects real-world data from about 5000 patients diagnosed with significant LMCA stenosis across multiple centers in the Asia-Pacific region. Participants diagnosed with unprotected LMCA stenosis of more than 50% blockage will be followed as they receive various treatments determined by their doctors, including medications, PCI with drug-eluting stents, or CABG. The study does not assign treatments but records outcomes as patients receive these therapies in standard care. Data collection occurs prospectively in this observational registry to reflect real-world treatment patterns. Throughout the study, participants will be monitored for up to 10 years to track important outcomes such as death, cardiac death, myocardial infarction, cerebrovascular events, and the need for repeat interventions. Additional assessments include rehospitalization and stent-related complications. Data is collected through clinical follow-ups as per the study schedule. This long-term observation aims to understand the comparative effectiveness and safety of treatments for unprotected LMCA disease in everyday medical practice.

Age: 18Years +All Genders
42 locations
P

Actively Recruiting

Researchers are studying patients with newly diagnosed H3 K27M-mutant diffuse glioma to see if the drug dordaviprone ONC201 after standard radiotherapy can help extend overall survival and delay disease progression. This international Phase 3 trial is randomized, double-blind, and placebo-controlled to carefully evaluate treatment effects in this specific patient group. Participants must have a confirmed diagnosis of this glioma subtype and have completed frontline radiotherapy. Participants are randomly assigned to one of three groups dordaviprone taken twice weekly, dordaviprone taken once weekly, or a matching placebo. Dosing is adjusted based on body weight, with a standard dose of 625 mg for patients weighing 52.5 kg or more. The study treatment starts after completion of radiotherapy and continues under close monitoring. Throughout the study, participants undergo regular assessments including brain MRIs, laboratory tests, and evaluations of neurological function and quality of life. Researchers will monitor overall survival over approximately 44 months, as well as progression-free survival, corticosteroid use, performance status, and symptom changes. Safety and lab parameters will be tracked closely to understand treatment effects and participant well-being during the trial period.

All AgesAll GendersPhase 3
162 locations